Key result
Nonfluoroscopic catheter ablation using simplified electroanatomic marker annotation for supraventricular tachycardias during pregnancy is described, but no quantitative results are reported.
Why the study?
Supraventricular tachycardias during pregnancy carry substantial risks to maternal and fetal health, and medical management with antiarrhythmic drugs presents significant potential adverse effects.
May offer medication-sparing option for refractory SVT in pregnancy; extends sparse case experience but leaves open need for prospective data.
Hemodynamic, autonomic, and hormonal changes during pregnancy may predispose women to the occurrence of new-onset and recurrent arrhythmias.1–3 Supraventricular tachycardias (SVTs) are predominant in this specific cohort.4 Their occurrence during pregnancy may be associated with an increased risk of maternal mortality and may influence the outcome of pregnancy.1,5 Pregnant patients with symptomatic arrhythmias might be managed medically, however, the potential adverse effects of antiarrhythmic medications remain substantial.
No takes yet. Share an insight, caveat, or question.
Kłębukowska et al. (2024) studied Supraventricular tachycardias during pregnancy. Nonfluoroscopic catheter ablation using simplified electroanatomic marker annotation was evaluated. Nonfluoroscopic catheter ablation using simplified electroanatomic marker annotation for supraventricular tachycardias during pregnancy is described, but no quantitative results are reported.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: